Business
Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
BOSTON, April 09, 2026--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that Company management will present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16th, 2026 at 12:45 p.m. ET.
About this update from Sensei Biotherapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/0d91fd4e69e9523612766e4259ae3d27"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MqBnf1XnP22fug0eiXL1tA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/0d91fd4e69e9523612766e4259ae3d27","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/4QoCFADWK2YuyQzWjms6FQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/0d91fd4e69e9523612766e4259ae3d27","width":1024,"height":512}},"lazy":false},{"type":"text","content":"BOSTON, April 09, 2026--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that Company management will present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16th, 2026 at 12:45 p.m. ET.","length":242,"tagName":"p"},{"type":"text","content":"The live webcast of the presentation may be accessed via the Events and Presentations section of the Sensei website at investors.senseibio.com. A replay of the webcast will be available for approximately 90 days following the event.","length":232,"tagName":"p"},{"type":"text","content":"About Sensei Biotherapeutics","length":28,"tagName":"p"},{"type":"text","content":"Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. Following the acquisition of Faeth Therapeutics, Sensei's lead program is PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. Sensei is also completing a Phase 1/2 trial of solnerstotug, its V-domain Ig suppressor of T cell activation (VISTA) inhibitor, in patients with advanced solid tumors. Sensei intends to use its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, please visit www.senseibio.com and follow the company on X @SenseiBio and LinkedIn.","length":838,"tagName":"p"},{"type":"text","content":"View source version on businesswire.com: https://www.businesswire.com/news/home/202...